Marc de Garidel
Marc de Garidel is the CEO of Cincor Pharma since July 1,2021, a private biotechnology company dedicated to developing a novel treatment against hypertension. Prior to joining CinCor, Mr. de Garidel served as CEO of Corvidia Therapeutics, a private Boston-based cardiorenal-focused clinical-stage company that was acquired by Novo Nordisk in August 2020 for $2.1 billion. From 2010 to 2016, he served as CEO and Chairman of Ipsen SA’s board of directors, where he led a significant transformation of the Company, effecting a three-fold increase in market capitalization, launching the blockbuster oncology drug Somatuline® Depot (lanreotide) in the U.S., and completing the ex-U.S. commercialization deal with Exelixis on CABOMETYX® (cabozantinib). Mr. de Garidel still serves as Chairman of Ipsen’s Board of Directors. Prior to joining Ipsen, Mr. de Garidel spent 15 years at Amgen Inc., initially joining as the company’s chief financial officer in Europe and ultimately leading the large international south region as a regional vice president. He began his career at Eli Lilly and Company, where he worked in the U.S., France, and Germany in a variety of roles in sales, marketing, finance, and human resources. Other active Board roles held by Mr. de Garidel include Cincor Pharma, Claris Biotherapeutics, Inc. and AZTherapies, Inc. Mr. de Garidel received a master’s degree in Civil Engineering from Ecole Spéciale des Travaux Publics in Paris, a master’s degree in Management from the Thunderbird School of Global Management and completed the Advanced Management Program (Executive MBA) at Harvard Business School. He has had an extensive non-profit responsibility as VP of EPFIA (Europe Pharma Association) for three years as well as chairing the French pharma association G5 for six years. Marc de Garidel is a recipient of the French Legion of Honor.